These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 7516085

  • 1. Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia.
    Kuniyoshi M, Nakamura J, Miura C, Inanaga K.
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):339-46. PubMed ID: 7516085
    [Abstract] [Full Text] [Related]

  • 2. Effects of mianserin on negative symptoms in schizophrenia.
    Mizuki Y, Kajimura N, Imai T, Suetsugi M, Kai S, Kaneyuki H, Yamada M.
    Int Clin Psychopharmacol; 1990 Apr; 5(2):83-95. PubMed ID: 1696292
    [Abstract] [Full Text] [Related]

  • 3. Biogenic amine metabolites in plasma of drug-naive schizophrenic patients: associations with symptomatology.
    Markianos M, Botsis A, Arvanitis Y.
    Biol Psychiatry; 1992 Aug 01; 32(3):288-92. PubMed ID: 1384728
    [Abstract] [Full Text] [Related]

  • 4. Effects of mianserin in chronic schizophrenia.
    Mizuki Y, Kajimura N, Kai S, Suetsugi M, Ushijima I, Yamada M.
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 Jul 01; 16(4):517-28. PubMed ID: 1641495
    [Abstract] [Full Text] [Related]

  • 5. Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia.
    Watanabe K, Miura I, Kanno-Nozaki K, Horikoshi S, Mashiko H, Niwa S, Yabe H.
    Psychiatry Res; 2015 Dec 15; 230(2):419-23. PubMed ID: 26416588
    [Abstract] [Full Text] [Related]

  • 6. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK, Colison J, Bartko JJ, Doran AR, Konicki PE, Potter WZ, Pickar D.
    Arch Gen Psychiatry; 1993 Aug 15; 50(8):606-14. PubMed ID: 7688209
    [Abstract] [Full Text] [Related]

  • 7. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S, Iwamoto N, Arai H.
    Biol Psychiatry; 1997 Apr 15; 41(8):857-64. PubMed ID: 9099412
    [Abstract] [Full Text] [Related]

  • 8. [Plasma levels of MHPG, HVA and total 5-HIAA in depression. Preliminary study].
    Raucoules D, Levy C, Azorin JM, Bruno M, Valli M.
    Encephale; 1992 Apr 15; 18(6):611-6. PubMed ID: 1285270
    [Abstract] [Full Text] [Related]

  • 9. Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanillic acid, 5-hydroxyindoleacetic acid, dihydroxyphenylethyleneglycol and clinical evaluations.
    Aymard N, Viala A, Clement MN, Jacquot M, Vacheron MN, Gauillard J, Caroli F.
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jun 15; 26(5):975-88. PubMed ID: 12369274
    [Abstract] [Full Text] [Related]

  • 10. Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
    Bowers MB, Mazure CM, Nelson JC, Jatlow PI.
    Biol Psychiatry; 1992 Dec 15; 32(12):1102-7. PubMed ID: 1477190
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF.
    Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathé AA.
    J Clin Psychopharmacol; 2010 Oct 15; 30(5):496-503. PubMed ID: 20814316
    [Abstract] [Full Text] [Related]

  • 13. Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine.
    Hatzimanolis J, Lykouras L, Markianos M, Oulis P.
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct 15; 22(7):1077-85. PubMed ID: 9829289
    [Abstract] [Full Text] [Related]

  • 14. Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy.
    Hori H, Yoshimura R, Katsuki A, Atake K, Igata R, Konishi Y, Nakamura J.
    World J Biol Psychiatry; 2017 Aug 15; 18(5):401-408. PubMed ID: 27409727
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
    Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ.
    Arch Gen Psychiatry; 1990 Jul 15; 47(7):641-8. PubMed ID: 1694425
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia.
    Shiloh R, Zemishlany Z, Aizenberg D, Valevski A, Bodinger L, Munitz H, Weizman A.
    Int Clin Psychopharmacol; 2002 Mar 15; 17(2):59-64. PubMed ID: 11890187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.